The company will develop a regenerative medicine platform that could substitute multiple types of cells destroyed by inherited and age-linked ocular ailments. Credit: wavebreakmedia /

Tenpoint Therapeutics has raised Series A funds of $70m to develop engineered cell-based therapies to reverse vision loss. 

Seed investors F-Prime Capital, Sofinnova Partners and British Patient Capital led the financing round, with Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund among others taking part.

The company will utilise the financing to develop a regenerative medicine platform that could substitute multiple types of cells that are destroyed by inherited and age-linked ocular ailments. 

Tenpoint Therapeutics CEO Eddy Anglade stated: “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue. 

“At Tenpoint, we are focused exclusively on the eye and on harnessing recent advances in regenerative biology to advance our therapies as we work to change the future for people with vision loss by addressing its underlying causes.”

The company is currently developing methods to create tailored ocular cell types ex vivo and in vivo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

F-Prime and Sofinnova Partners, the first investors of Tenpoint, backed the initial operational and technological growth of the company.

Sofinnova Partners managing partner Graziano Seghezzi stated: “Tenpoint stands out in the realm of regenerative medicine, with an innovative approach that could ultimately provide a transformative cure to many causes of blindness for millions of patients around the world.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.